Skip to main content

S2.

Clinical performance of physician- and self-collected careHPV testing in primary and triage screening strategies, stratified by age, for CIN3+ detection among 2,337 women

Primary screening Triage strategy Age (year) CIN3+ (N=23) % (95% CI) Colposcopy per CIN3+ (N)
Sensitivity Specificity PPV NPV Youden’s index
HPV, human papillomavirus; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; RLU/CO, relative light units/cutoff; HC2, Hybrid Capture 2; ASC-US+, atypical squamous cells of undetermined significance or worse; VIA, visual inspection with acetic acid; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
Physician-careHPV ≥1.0 RLU/CO ASC-US+ 30 to 44 10 83.3
(55.2–95.3)
94.5
(93.2–95.6)
12.0
(6.7–20.8)
99.8
(99.4–100)
77.9 8.3
45 to 54 9 81.8
(52.3–94.9)
92.1
(90.2–93.6)
10.5
(5.6–18.7)
99.8
(99.2–99.9)
73.9 9.6
VIA 30 to 44 7 58.3
(32.0–80.7)
98.6
(97.8–99.1)
26.9
(13.7–46.1)
99.6
(99.1–99.8)
56.9 3.7
45 to 54 5 45.5
(28.0–78.7)
99.1
(98.3–99.5)
35.7
(16.3–61.2)
99.4
(98.7–99.7)
44.5 2.8
Self-careHPV ≥1.0 RLU/CO ASC-US+ 30 to 44 9 75.0
(46.8–91.1)
95.4
(94.2–96.4)
12.9
(6.9–22.7)
99.8
(99.3–99.9)
70.4 7.8
45 to 54 7 63.6
(35.4–84.8)
94.9
(93.3–96.1)
12.3
(6.1–23.2)
99.6
(98.9–99.8)
58.5 8.1
VIA 30 to 44 7 58.3
(32.0–80.7)
98.6
(97.8–99.1)
26.9
(13.7–46.1)
99.6
(99.1–99.8)
56.9 3.7
45 to 54 3 27.3 (9.7–56.6) 99.3 (98.4–99.6) 30.0 (10.8–60.3) 99.2 (98.4–99.6) 26.6 3.3
Physician-HC2 ≥1.0 RLU/CO ASC-US+ 30 to 44 10 83.3
(55.2–95.3)
93.3
(91.8–94.5)
10.0
(5.5–17.4)
99.8
(99.6–100)
76.6 10.0
45 to 54 11 100
(74.1–100)
91.8
(89.9–93.4)
12.1
(6.9–20.4)
100
(99.4–100)
91.8 8.3
VIA 30 to 44 7 58.3
(32.0–80.7)
98.2
(97.3–98.8)
22.6
(11.4–39.8)
99.6
(99.1–99.8)
56.5 4.4
45 to 54 6 54.5
(28.0–78.7)
98.9
(98.0–99.4)
35.3
(17.3–58.7)
99.5
(98.0–99.4)
53.4 2.8